Reported September 6, 2018, 'FDA to evaluate potential risk of neural tube birth defects with HIV medicine dolutegravir (Juluca, Tivicay, Triumeq)' - FDA
Portfolio Pulse from Benzinga Newsdesk
The FDA is evaluating the potential risk of neural tube birth defects associated with the HIV medicine dolutegravir, which is found in Juluca, Tivicay, and Triumeq. This evaluation could impact companies involved in the production and distribution of these medications.
July 05, 2024 | 3:02 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
The FDA's evaluation of dolutegravir's potential risk of neural tube birth defects could negatively impact GSK, as they are involved in the production of Juluca, Tivicay, and Triumeq.
GSK is directly involved in the production of the medications under evaluation. Any negative findings could lead to regulatory actions or decreased sales, impacting GSK's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
NEGATIVE IMPACT
Pfizer (PFE) may also be impacted by the FDA's evaluation of dolutegravir, as they have partnerships and interests in the HIV medication market.
While Pfizer is not the primary producer, their involvement in the HIV medication market means they could face indirect impacts from any regulatory changes or market reactions.
CONFIDENCE 70
IMPORTANCE 60
RELEVANCE 50